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T hyroid hormone receptors (TRs) are ligand-dependent transcription factors that regulate growth, differentiation, and maintenance of metabolic homeostasis. TRs are encoded by ␣ and ␤ genes, located on chromosomes 3 and 17, respectively. Alternative splicing of the primary transcripts gives rise to four thyroid hormone (T3)-binding proteins, ␣1, ␤1, ␤2, and ␤3, which bind to thyroid hormone response elements (TRE) on the promoters of T3-target genes. The consensus TREs consist of two half-sites with the sequence of (A͞G)GGT(C͞G͞A)A that are arranged as a direct repeat, separated by four nucleotides (DR4), palindrome (Pal), or inverted repeat, separated by six nucleotides (F2) (1) . The transcriptional activity of TRs is modulated by a host of coregulatory proteins (2) . In the absence of T3, TRs repress basal transcription through association with a variety of corepressors, such as NCoR and the silencing mediator for retinoid and thyroid hormone receptors. Binding of T3 induces structural changes to release the corepressors and to allow recruitment of coactivators, such as the steroid hormone receptor coactivator-1 (SRC-1) and other p160 family members. Corepressors harbor deacetylase activity that acts to modify the chromatin structure so as to limit the access of basal transcriptional machinery. Coactivator complexes, in contrast, harbor histone acetyltransferase and methyltransferase activities that facilitate transcription by rendering chromatin more accessible to transcription factors (1, 2) .
We have created a mutant mouse by targeting a mutation (PV) to the TR␤ gene locus (TR␤PV mice) (3) . PV was identified in a patient (PV) with resistance to thyroid hormone (RTH) (4) . RTH is caused by mutations of the TR␤ gene and manifests symptoms due to decreased sensitivity to T3 in target tissues (5) . The most common form of RTH is familial, with autosomaldominant inheritance (5) . Patients are usually heterozygotes, with only one mutant TR␤ gene, and the symptoms are mild. Moreover, clinical manifestations are variable among families with RTH and also among affected family members. Clinical features include goiter, short stature, decreased weight, hypercholesterolemia, tachycardia, hearing loss, attention deficithyperactivity disorder, decreased IQ, and dyslexia (5) . One single patient homozygous for a mutant TR␤ with a complex phenotype of extreme RTH has been reported (6) . PV has a C-insertion at codon 448 that produces a frame-shift in the carboxyl-terminal 14 amino acids of TR␤1 (4) . PV has completely lost T3 binding and exhibits potent dominant negative activity (7) . Patient PV has only one mutated TR␤ allele and exhibits short stature and delayed bone age, similar to other heterozygous RTH patients (5) .
Remarkably, as homozygous TR␤PV mice (TR␤ PV/PV mice) age, they spontaneously develop follicular thyroid carcinoma through a pathological progression resembling human thyroid cancer (8) . Gene-expression profilings of thyroid tumors in TR␤ PV/PV mice have identified the repression of the peroxisome proliferator-activated receptor ␥ (PPAR␥)-signaling pathway as one of the altered pathways that contribute to thyroid carcinogenesis (9) . These findings suggest that TR␤ mutants could cross talk with the PPAR␥-signaling pathway.
PPARs are also members of the nuclear hormone-receptor superfamily and play an important role in adipogenesis, cell cycle control, apoptosis, and carcinogenesis. PPARs are activated by a broad class of structurally diverse xenobiotic chemicals termed peroxisome proliferators (10, 11) . PPARs bind to peroxisome proliferator response elements, a direct repeat of the AGG(T͞ A)CA binding motif, separated by one nucleotide (DR1). Similar to TRs, PPARs require heterodimerization with retinoid X receptors (RXRs) for optimal binding to DNA to activate peroxisome proliferator-target genes (12) . Cell-based studies indicate that PPARs are able to selectively inhibit the transcrip-tional activity of TRs by competing for RXR (13, 14) . Conversely, TR␣1 was shown to regulate the expression of acyl-CoA oxidase peroxisome proliferator response element (PPRE)-mediated transcriptional activity (15) , suggesting that these two receptors could regulate a similar subset of genes involved in maintaining lipid metabolism.
The observation that a TR␤ mutant, PV, represses the PPAR␥-signaling pathway in the thyroid of TR␤ PV/PV mice (9) prompted us to delineate its underlying molecular mechanisms. We found that, besides the liganded TR␤, the unliganded TR␤ and the mutant PV also compete with PPAR␥ for binding to PPRE as homodimers and heterodimers with PPAR␥ or with RXR. Cell-based studies indicate that the unliganded TR␤ and the mutant PV repress the troglitazone-dependent transcriptional activity of PPAR␥. Chromatin immunoprecipitation (CHIP) assay demonstrates that the repression is due to the recruitment of corepressors to the promoter of PPAR␥-target genes in vivo. Importantly, the recruitment of corepressors to the PPRE-bound PV on the promoter is T3-and troglitazoneindependent. Thus, the present study shows that PV is a dominant negative regulator of PPAR␥ action.
Materials and Methods
Mouse Strain and Cell Culture. The mice harboring the TR␤PV gene were prepared and genotyped as described in ref. (16) or pCLC51PV (17) , respectively]. SRC-1 expression vector (pIRES-SRC-1, 1 g) was cotransfected into cells in some experiments. Twenty-four hours after transfection, 20 M troglitazone or 100 nM T3 was added and incubated for an additional 24 h before harvest. All experiments were performed in triplicate and repeated three times. The results shown are the mean Ϯ SD.
EMSA. The double-stranded oligonucleotide containing the PPR E (PPR E-5Ј, GA ACGTGACCT T TGTCCTGGTC-CCCTTTGCT and PPRE-3Ј, GGGACCAGGACAAAGGT-CACGTTCGGGAAAGG) (the underlined portion of the sequence is the PPRE for Acyl-CoA oxidase, a target gene for PPAR␥) (18) was labeled with [ 32 P]dCTP similarly to the method described by Ying et al. (19) . Approximately 0. 
Results

PV Binds to PPRE as Heterodimers with PPAR␥ or RXR.
We have reported that PV represses troglitazone-dependent transcriptional activity of PPAR␥ in a cultured thyroid cell line, PC cells (19) . However, it was not clear by what mechanisms PV acts to repress the troglitazone-dependent transcriptional activity of PPAR␥. We hypothesized that the repression could be due to the competition of PV with PPAR␥ for binding to PPRE. Because it is unknown whether PV can bind to PPRE (DR1), we evaluated its binding to PPRE by EMSA. Fig. 1 , lane 2 shows that PPAR␥ binds to PPRE strongly as heterodimers with RXR␤ (band ''a''), but binding to PPRE as homodimers was not detectable under the experimental conditions ( Fig. 1, lane 9) . The latter was confirmed by supershifting the PPRE-bound PPAR␥͞PV to a more retarded position with anti-PV antibody T1 (Fig. 1 , lane 10, band ''c''). However, an irrelevant antibody failed to do so (Fig. 1, lane 11) . The use of anti-PPAR␥ antibody in the supershift experiments further confirms the binding of PPAR␥͞TR␤1 and PPAR␥͞PV heterodimers to PPRE (data not shown). Similar to the binding of TRs to TREs, the binding of TR␤1 or PV to PPRE as heterodimers was not affected by the ligand for TR␤1 (T3) or for PPAR␥ (troglitazone). The ligand-independent association of TR␤1 with PPAR␥ in cells was also demonstrated by coimmunoprecipitation experiments (data not shown).
TR␤1 or PV also bound to PPRE as heterodimers with RXR␤ ( Fig. 1, lanes 12 and 14, respectively) . This binding was con- firmed by supershifting the PPRE-bound TR␤1͞RXR␤ or PV͞ RXR␤ with anti-TR␤1 C4 or anti-PV T1 to a more retarded position (Fig. 1 , lane 13, band ''d'' and lane 15, band ''e,'' respectively). These results indicate that TR␤1 and the mutant PV can bind to PPRE as homodimers and as heterodimers with PPAR␥ or with RXR␤.
PV Inhibits the Binding of PPAR␥ with the RXR to Form PPRE-Bound
Heterodimers in a Dose-Dependent Manner. Because both PPAR␥ and TRs heterodimerize with RXR on their cognate hormoneresponse elements, the finding that both TR␤1 and PV bound to PPRE as heterodimers with RXR␤ or PPAR␥ prompted us to ask whether TR␤1 or PV could compete with PPAR␥ for binding to PPRE as heterodimers with RXR or PPAR␥. Fig. 2 shows that, indeed, compared with PPRE-bound PPAR␥͞RXR in the absence of TR␤1 (Fig. 2 A, lane 1) or PV (Fig. 2 A, lane 9) , binding of PPAR␥͞RXR␤ to PPRE was decreased in the presence of increasing concentrations of TR␤1 (Fig. 2 A, lanes  2-4) or PV (Fig. 2 A, lanes 10 -12) . This concentrationdependent decrease in the binding can be seen more readily in the autoradiogram with a shorter exposure (Fig. 2B , lanes 2-4 for TR␤1 and lanes 6-8 for PV).
To verify that TR␤1 or PV competed with PPAR␥ for binding to PPRE, anti-TR␤1 (C4) and anti-PV (T1) antibodies were used to confirm the formation of PPRE-bound TR␤1͞RXR␤ and TR␤1͞PPAR␥ or PV͞RXR␤ and PV͞PPAR␥ on PPRE by EMSA. As shown in Fig. 2 A, lanes 5-7, two more retarded supershifted bands (bands ''a'' and ''b'') were detected. On the basis of supershifted bands shown in Fig. 1 , lane 6 for TR␤1͞ PPAR␥͞C4 complexes and in Fig. 1 , lane 13 for TR␤1͞ RXR␤͞C4 complexes, the less-retarded band ''a'' in Fig. 2 A, lanes 5-7 represented TR␤1͞PPAR␥͞C4 complexes, and the more-retarded band ''b'' represented PPRE-bound TR␤1͞ RXR␤͞C4 complexes. The specificity of these supershifted bands was verified by using an irrelevant antibody MOPC, for which no supershifted band was noted in Fig. 2 A, lane 8. Because the PPRE-bound PV͞PPAR␥ or PV͞RXR␤ were supershifted to a similarly retarded position by T1, as shown in Fig. 1 , lanes 10 and 15, respectively, the more-retarded broad band c in Fig.  1 , lanes 13-15 represented both PV͞PPAR␥͞T1 and PV͞ RXR␤͞T1 complexes. Again, the specificity of supershifted band c was confirmed by using an irrelevant antibody MOPC, for which no supershifted band was observed in Fig. 1, lane 16 .
The intensities of the PPAR␥͞RXR␤ heterodimer bands shown in Fig. 2B were quantified, and the results are graphed in Fig. 2C . In these experiments, equal amounts of TR␤1 or PV proteins were added at each pair of corresponding lanes (i.e., Fig.  2C , lanes 2 and 6, lanes 3 and 7, and lanes 4 and 8 for TR␤1 and PV, respectively). No significant differences were observed in the extent of reduction of PPRE-bound PPAR␥͞RXR␤ by the presence of TR␤1 or PV proteins at the corresponding concentrations. These results suggest that PV and TR␤1 are similarly effective in competing with PPAR␥ for binding to PPRE as heterodimers with PPAR␥ or RXR␤.
PV Represses the Ligand-Dependent Transactivation of PPAR␥ in CV-1
Cells. The above EMSA results suggest that the repression of troglitazone-dependent PPAR␥-mediated transactivation by PV would not be limited to the mouse thyroid PC cells (19) . We therefore examined whether this repression also occurs in monkey CV-1 cells. The luciferase-reporter-containing PPAR␥ response element (AGGTACXAGGTCA, DR1) and mouse PPAR␥1 expression vector were cotransfected with or without TR␤1or PV into cultured CV-1 cells in the presence or absence of troglitazone or T3 (Fig. 3) . The transactivation activity of PPAR␥ was clearly stimulated by troglitazone (8.1-fold) (Fig. 3 , compare bar 2 with bar 1). In the absence of T3, increasing the concentration of unliganded TR␤1 repressed the troglitazonedependent transactivation activity of PPAR␥ (Fig. 3, bars 4 and 5, a 51% and 75% reduction at the TR␤1 expression plasmid concentrations of 0.2 and 1.0 g, respectively). Similar repression of the troglitazone-dependent transactivation activity of PPAR␥ by PV was also detected (Fig. 3, bars 7 and 8 ). In the presence of T3, however, a different profile of transactivation activity emerged. At a low concentration of TR␤1 expression plasmid (0.2 g), no repression of troglitazone-dependent transactivation activity of PPAR␥ was detected (Fig. 3 , compare bar 10 with bar 2), but, at a higher concentration of TR␤1 (1.0 g), repression of troglitazone-dependent transactivation activity of PPAR␥ was detected (60% reduction, Fig. 3 , compare bar 11 with bar 2). PV, however, repressed the troglitazone-dependent transactivation activity of PPAR␥ in a dose-dependent manner (54% and 81% for 0.2 and 1.0 g, respectively; Fig. 3 , compare bars 13 and 14 with bar 2), similar to that in the absence of T3 (Fig. 3, bars 7 and 8) . These results indicate that, in addition to PC cells, PV and the unliganded TR␤1 repressed the troglitazone-dependent transactivation activity of PPAR␥ in CV-1 cells.
NCoR Constitutively Associates with PPRE-Bound PV Independent of
Troglitazone or T3. It has been shown that TR␤ mutants interact aberrantly with corepressors such as NCoR and exhibit an impaired ability to dissociate from corepressors in the presence of T3 (23) . Importantly, a strong positive correlation was found between mutant-receptor interactions with corepressors and transcriptional silencing activity (24) . That PV, similar to the unliganded TR␤1, repressed the trogliotazone-dependent transcriptional activity of PPAR␥ (Fig. 3) suggests that PV could constitutively associate with corepressors, such as NCoR, and thereby prevent the recruitment of coactivators to the promoters of PPAR␥-target genes. Therefore, we used EMSA to assess ligand-independent association of PV with NCoR on PPRE (Fig.  4) . For control, we first confirmed that PPRE-bound unliganded TR␤1 associated with NCoR, as indicated by the presence of more retarded unliganded TR␤1͞NCoR complexes (Fig. 4,  compare lane 3 with lane 1) . Fig. 4, lanes 1 and 2 show that binding of TR␤1 to PPRE was T3-independent, similar to the binding of TR␤1 to TREs (1). Binding of T3 to TR␤1 released NCoR from the PPRE-bound TR␤1 (Fig. 4A, lane 4) . In the presence of T3, no association of NCoR with either PPREbound TR␤1 homodimers or heterodimers with PPAR␥ was found (Fig. 4A, compare lane 8 with lane 7) . Similar to the unliganded TR␤1, PV associated with NCoR in the absence of T3 as a homodimer (Fig. 4A, lane 11) or heterodimer (Fig. 4A,  lane 15) with PPAR␥. However, in contrast to the liganded TR␤1, the presence of T3 could not release NCoR from PPRE-bound PV homodimers (Fig. 4 A, lane 12) or heterodimers (Fig. 4A, lane 16) . These results indicate that PPREbound PV constitutively associates with NCoR.
Whether the PPAR␥ ligand troglitazone affected the association of NCoR with PPRE-bound TR␤1͞PPAR␥ or PV͞ PPAR␥ heterodimers was also examined. Fig. 4B shows that troglitazone did not affect the binding of TR␤1 to PPRE as heterodimers with PPAR␥ (Fig. 4B, lanes 1 and 2) . It also had no effect on the binding of PV to PPRE (Fig. 4B, lanes 5 and 6) . In contrast to T3, troglitazone (Fig. 4B, lane 4) could not release NCoR from the PPRE-bound unliganded TR␤1 (Fig. 4B , compare lane 4 with lane 3) and the PPRE-bound PV (Fig. 4B , compare lane 8 with lane 7). These findings indicate that the release of PPRE-bound TR␤1 or PV heterodimers with PPAR␥ is troglitazone-independent. These results suggest a polarity in the sensitivity of the ligand in releasing NCoR from the PPREbound unliganded TR␤1͞PPAR␥ and PV͞PPAR␥ and that the unliganded TR␤1 and PV play a dominant role in affecting their dimeric partner PPAR␥.
SRC1-Mediated Transactivation Activity of PPAR␥ Is Abrogated in the
Presence of PV. SRC-1 is a coactivator for TR and PPAR␥ that plays a crucial role in their transcription activation upon ligand binding (2) . Transcriptional activation by liganded TR is mediated through interaction with the coactivators and recruitment of histone acetyltransferase activities. The above EMSA findings predict that PPRE-bound unliganded-TR␤1͞PPAR␥ and PV͞PPAR␥ would fail to recruit coactivators such as the SRC-1, a coactivator for TR and PPAR␥. To test this hypothesis, we carried out a transient transfection reporter assay. Fig. 5, bar 4 shows that SRC-1 enhanced the troglitazone-dependent PPAR␥ transactivation (2.7-fold; Fig. 5 , compare bar 4 with bar 2). In the absence of T3, the unliganded TR␤1 repressed (60-70%) troglitazone-dependent PPAR␥ transactivation in the absence of SRC-1 (Fig. 5 , compare bar 6 with bar 2) or in its presence (Fig. 5, compare bar 8 with bar 4) . A similar extent of repression of the troglitazone-dependent PPAR␥ transactivation was observed for PV (Fig. 5 , compare bar 10 with bar 2 and bar 12 with bar 4). However, in the presence of T3 and TR␤1, SRC-1 potentiated the troglitazone-independent (Fig. 5 , compare bar 15 with bar 13) and -dependent (Fig. 5 , compare bar 16 with bar 14) PPAR␥ transactivation Ϸ3-fold. In contrast, the SRC-1 potentiation of PPAR␥ transactivation was abrogated by PV, despite the presence of T3 (Fig. 5 , compare bar 19 with bar 17) or together with troglitazone (Fig. 5, compare bar 20 with bar 18 ). Taken together, these results suggest that constitutive association of PV with corepressors prevents the recruitment of SRC-1 to the PPAR␥͞PV complexes in the presence of troglitazone.
Recruitment of PV to the Promoter of a PPAR␥-Target Gene, the LpL, in the Thyroid of TR␤ PV͞PV Mice. To further support the notion that constitutive association of PV with NCoR leads to the repression of PPAR␥ transcription activity, we carried out the CHIP assays using thyroid nuclear extracts of TR␤ PV/PV mice to determine whether PV and NCoR were recruited to the promoter of the LpL gene (LpL) in vivo. LpL is a direct target gene of PPAR␥ that contains a PPRE in its promoter between Ϫ169 and Ϫ157 (25) . Its mRNA expression is repressed in the thyroid of TR␤ PV/PV mice (9). Fig. 6 shows the recruitment of PV, NCoR, and PPAR␥ to the LpL promoter by CHIP assays. Mutant PV was clearly recruited to the LpL promoter as an 81-bp PCR product, detected when DNA-protein complexes were immunoprecipitated by either polyclonal anti-PV-specific antibodies T1 (Fig. 6, lane 8) or the monoclonal antibody #302 (Fig. 6, lane  10) . As expected, no positive signals were detected in wild-type mice (Fig. 6, lanes 7 and 9) . A weak signal for wild-type TRs was detected in wild-type mice (Fig. 6, lane 11) when anti-TR antibody (C4) was used in the assay but not in TR␤ PV/PV mice (Fig. 6, lane 12) . That NCoR was also recruited to the LpL promoter was demonstrated in TR␤ PV/PV mice by the positive signal shown in Fig. 6 , lane 14 but not in wild-type mice (Fig. 6,  lane 13) . A stronger signal was shown for wild-type mice (Fig. 6 , lane 15) than for TR␤ PV/PV mice (Fig. 6, lane 16) , when anti-PPAR␥ antibody was used to immunoprecipitate the DNAprotein complexes, indicating that less PPAR␥ was recruited to the LpL promoter in TR␤ PV/PV mice. The weaker signal detected in TR␤ PV/PV mice (Fig. 6, lane 16 ) most likely reflects the competition of PV with PPAR␥ for binding to LpL PPRE (see EMSA results and transcription assays in Figs. 2 and 3 , respectively). Fig. 6 , lanes 3 and 4 were the negative controls in which the IgGs were used for immunoprecipitation.
Discussion
This study shows complex regulation of the PPAR␥ activity by the liganded, unliganded, and mutated TR␤1. Consistent with findings by others (13) (14) (15) 26) , the liganded TR␤1 can bind to PPRE as heterodimers with RXR. Interestingly, this study also shows that TR␤1 can bind to PPRE as heterodimers with PPAR␥, even though the binding of TR␤1͞PPAR␥ and TR␤1͞ RXR heterodimers is relatively weaker than the binding of PPAR␥͞RXR to PPRE. Consistent with the in vitro EMSA study, the cell-based study shows that the liganded TR␤1 itself can activate PPRE-mediated transcriptional activity in the absence of PPAR␥ ligand (troglitazone). However, in the presence of troglitazone, the T3-bound TR␤1 could inhibit troglitzonedependent PPAR␥ transcriptional activity by competition with PPAR␥ for binding to PPRE and by sequestering RXR. This study further demonstrates the repression of the transcriptional activity of PPAR␥ by the T3-bound TR␤1 and PV in monkey CV-1 cells, suggesting that the crosstalk between the TR-and PPAR␥-signaling pathways is not limited to thyroid cells (19) . The in vitro DNA-binding study shows that the unliganded TR␤1 and PV competes with PPAR␥ for binding to PPRE and inhibits the binding of the transcriptionally active PPAR␥͞RXR to PPRE. The cell-based transcriptional analysis further shows the repression of troglitzone-dependent PPAR␥ transcription activity by the unliganded TR␤1 and PV. That no such transcription repression by a DNA-binding-deficient TR␤1 mutant further (data not shown) supports the critical role of competition of TR␤1 or PV with PPAR␥ for binding to PPRE in mediating the repression of PPAR␥ transcription. Further analysis indicates that the transcriptional repression is due to association of the unliganded TR␤1 or PV with corepressors, thereby resulting in 6 . Recruitment of NCoR to PPRE-bound PPAR␥ and PV in the promoter of the LpL gene in the thyroid of TR␤ PV/PV mice by CHIP assay. Thyroid nuclear extracts from wild-type (W) or TR␤ PV/PV mice (P) were processed for CHIP assay, as described in Materials and Methods. Anti-PPAR␥, anti-NCoR, anti-PV (polyclonal antibody, T1, or monoclonal antibody #302) (17) antibodies, and IgG (for negative controls) were used for immunoprecipitation. The precipitated DNA was amplified by PCR with primers specific for the LpL PPRE, and the products were analyzed. A representative example is shown here, but the experiments were repeated three times with similar results.
failure to recruit coactivators for transcriptional activation. Thus, this study has provided insights into the molecular mechanisms by which the unliganded TR␤1 or PV negatively regulates the activity of PPAR␥.
A recent report indicates that PPAR␥ is associated with corepressors on the promoter of glycerol kinase, a PPAR␥-target gene in adipocytes (27) . Binding of PPAR␥ ligands triggers the release of corepressors, resulting in the activation of this target gene (27) . However, it is important to note that the association of a corepressor, such as NCoR, with the unliganded TR␤1 and PV results in the troglitazone-independent repression of PPAR␥ (Fig. 5) . This effect would suggest that an association of NCoR with the unliganded TR␤1 in unliganded TR␤1͞PPAR␥ or with PV in PV͞PPAR␥ heterodimers prevents either the binding of troglitazone to the heterodimeric partner PPAR␥ or the recruitment of coactivators, such as SRC-1, to the liganded PPAR␥. The former possibility is favored, because, in an analogy to RXR͞TR, formation of this heterodimer is known to prevent RXR from binding its ligands (12) . Although T3 can relieve the repression effect of unliganded TR␤1͞PPAR␥ on troglitazonedependent transcriptional activity of PPAR␥ by releasing corepressors, it cannot relieve the repression effect on PV͞PPAR␥, because PV cannot bind T3. Thus, PV is a constitutive dominant negative regulator of PPAR␥ action.
It has been recognized that peroxisome proliferators and T3 have overlapping metabolic effects and regulate a similar subset of genes involved in maintaining lipid homeostasis. Crosstalk between TR-and PPAR-signaling pathways has been documented by the findings that PPAR␣ negatively regulates the expression of certain thyroid hormone target genes (13, 26) , and, conversely, a PPAR␣-target gene, acyl-CoA oxidase, was shown to be modulated by the liganded TR␣1 (15) . The present findings, however, have revealed a significantly expanded scope by which TR can regulate the PPAR␥-signaling pathways, in that not only the liganded TR but also the unliganded TR and mutated TR can act to affect PPAR␥ transcriptional activity.
That the unliganded TR and mutated TR␤ repress the liganddependent transcriptional activity of PPAR␥ has important physiological implications. In rats treated with T3 to reach a hyperthyroid state, induction of a key enzyme in cholesterol metabolism, CYP4A2, by pharmacological doses of dehydroepiandrosterone (DHEA) (a peroxisome proliferating agent) is completely inhibited at the mRNA level. In thyroidectomized rats, basal expression of CYP4A2 mRNA is decreased compared with euthyroid controls (28) . These in vivo observations are consistent with the regulation of PPAR-signaling pathways by the liganded and unliganded TR demonstrated in this study. In humans, overt hypothyroidism is associated with dyslipidemia. In these patients, there is an increase in serum total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, lipoprotein levels, and, possibly, triglyceride levels. These abnormalities could be due to dysfunction of T3-target genes directly mediated by TRs. However, it is entirely possible that these abnormalities are partly mediated through the repression of PPAR-target genes by the unliganded TRs. The identification of PPAR-target genes affected by unliganded TRs awaits future studies.
The in vivo functional consequence of the repression of PPAR␥-signaling pathways by PV is evident in the thyroid of TR␤ PV/PV mice. The expression of a PPAR␥ downstream target gene, LpL, is down regulated 5-fold by the expression of PV in TR␤ PV/PV mice (9) . The repression of the PPAR␥-signaling pathways is one of the altered pathways that contribute to the carcinogenesis of the thyroid (9) . Thus, in addition to affecting metabolic pathways and lipid homeostasis, the repression of the PPAR␥-signaling pathways by PV could lead to aberrant regulation of PPAR␥ downstream genes to promote the development and progression of thyroid cancer.
In addition to the PV mutation, many other dominantly negative TR␤ mutants are known to cause resistance to thyroid hormone (5). Their dominant negative activity is regulated by many factors, including the site of mutations and the extent of aberrant interaction with corepressors, leading to variable clinical manifestations (23, 29) . These TR␤ mutants, in addition to affecting the expression of T3-target genes through their dominant negative activity on the wild-type TRs, could also aberrantly affect the expression of PPAR␥-target genes. Therefore, the discovery that the PPAR␥-signaling pathway is negatively regulated by the unliganded and mutated TR␤ broadens our understanding of the regulation of genes involved in metabolic pathways, lipid homeostasis, and carcinogenesis.
